Quick Answer
Lyell Immunopharma, Inc. reported Diluted EPS of $16.06 per share (loss) for fiscal year 2025.
Lyell Immunopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$16.06 | +38.8% |
| 2024 | -$26.23 | -40.3% |
| 2023 | -$18.70 | -2427.0% |
| 2022 | -$0.74 | +59.8% |
| 2021 | -$1.84 | +88.3% |
| 2020 | -$15.69 | +34.7% |
| 2019 | -$24.04 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.13 | +38.8% | +26.3% |
| June 30, 2025 | -$2.89 | +19.5% | -1505.6% |
| March 31, 2025 | -$0.18 | +25.0% | +94.8% |
| September 30, 2024 | -$3.48 | -1640.0% | +3.1% |
| June 30, 2024 | -$3.59 | -1280.8% | -1395.8% |
| March 31, 2024 | -$0.24 | +11.1% | -20.0% |
| September 30, 2023 | -$0.20 | +28.6% | +23.1% |
| June 30, 2023 | -$0.26 | -73.3% | +3.7% |
- Lyell Immunopharma, Inc. showed an increase of +38.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Lyell Immunopharma, Inc.’s diluted eps has grown by 33.2% (from $24.04 per share (loss) to $16.06 per share (loss)).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: